Dr. Adi Diab

Dr. Adi Diab |Clyto Access

The University of Texas MD Anderson Cancer Center, USA

Editorial Board Member

Expertise: Dynamics of patient's immune response to the tumor, Tumor ablation, Cryoablation, RFA or radiation therapy

Dr. Diab is a clinical investigator whose research is focused on developing new Immunotherapeutic Strategies that will improve clinical outcomes in patients. Building on his extensive background in immunology in general and tumor immunology specifically, Dr. Diab is leading multiple clinical trials involving novel vaccines for patients with Melanoma. In addition he is leading a program for Interventional Immunotherapy that was established to develop Intratumoral Therapeutic strategies in combination with Systemic therapy; designed to improve clinical outcome and allow better understanding of the dynamics of each patient’s immune response to the tumor. These strategies include tumor ablation such as Cryoablation, RFA or Radiation therapy as well as direct intratumoral injection of immune modulation agents such as TLR agonists and other immune-stimulating agents.

He has authored or co-authored over thirty scientific publications and abstracts and serves as a reviewer for the Journal of Immunotherapy and the Journal of the American Society of Hematology.  

Dr. Diab received his medical degree from St. George’s University.  He completed a research fellowship in immunology at Memorial Sloan-Kettering Cancer Center.  Following his residency at New York University Medical Center, Dr. Diab completed additional clinical fellowships at Memorial Sloan-Kettering Cancer Center in hematology oncology and breast medical oncology.  

Dr. Diab is board certified in internal medicine.

Related Journals & Conferences :

Current Research and Therapy in Cancer